This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Acapodene - ADT

GTx, Inc.

Drug Names(s): toremifene citrate (80 mg)

Description: BioMedTracker has two separate profiles for Acapodene. Please also see Acapodene - PIN.

Acapodene is a Selective Estrogen Receptor Agonist (SERM) and preferentially modulates (antagonist effect) estrogen beta receptors, which are found in preponderance on prostate cells. This effect inhibits prostate tumor growth and has applications in prostatic intraepithelial neoplasia (PIN).

Acapodene also modulates (agonist effect) estrogen receptors in bone tissue, resulting in increase in ostegenic activity . This effect increases bone mineral density and may prevents bone loss that occurs due to androgen-deprivation therapy for prostate cancer.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

In 2000, GTx in-licensed toremifene from Orion to develop Acapodene for indications in men's health. In 2004, GTx's license and supply agreement with Orion was expanded to give GTx exclusive rights to toremifene in all indications in the U.S. and all indications except breast cancer in all other countries.

GTx and Ipsen announced in September 2006 that they entered into a definitive agreement under which Ipsen will have an exclusive license to develop and market GTx's Acapodene in all indications except breast cancer, in Europe (European Union, Switzerland, Norway, Iceland, Lichtenstein and the Commonwealth of Independent States) (European Territory).

Ipsen will pay to GTx euro 23 million (approximately $30 million based on current exchange rates) upfront payment and fees. In addition, GTx may receive milestone payments from Ipsen of euro 39 million ($50 million) for Acapodene, depending on the successful development...See full deal structure in Biomedtracker

Partners: Orion Corporation Ipsen SA

Acapodene - ADT News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug